VIGILANCIA FARMACOLÓGICA EN LA DISFUNCIÓN ENDOTELIAL PULMONAR HIPERTENSIÓN ARTERIAL PULMONAR IDOPÁTICA. A propósito de un caso
VIGILANCIA FARMACOLÓGICA EN LA DISFUNCIÓN ENDOTELIAL PULMONAR HIPERTENSIÓN ARTERIAL PULMONAR IDOPÁTICA. A propósito de un caso
-
DOI: https://doi.org/10.22533/at.ed.1594412429047
-
Palavras-chave: Hipertensión pulmonar, Farmacovigilancia, Bosentan, Macitentan,
-
Keywords: Pulmonary hipertensión, Pharmacovigila Bosentan, Macitentan.
-
Abstract: Pulmonary hypertension is a major health problem worldwide. All age groups are affected. Current estimates indicate a prevalence of around 1% of the global population. PH is a pathophysiological disorder that can be found in numerous clinical entities and can be associated with multiple cardiovascular and respiratory diseases. Due to the complexity of the treatment, a multidisciplinary approach is necessary, in which the patient actively participates with the medical team. We present the case of a patient diagnosed with idiopathic pulmonary arterial hypertension (IPAH) initially treated with a dual endothelin receptor antagonist (ERA) (Bosentan) and Tadalafil and in whom pharmacological monitoring managed to associate a significant increase in transaminases described as toxicity produced by Bosentan. This determined a change in treatment, where Bosetan was replaced by Macitentan, demonstrating the patient's clinical improvement. Active FVG processes provide relevant data regarding new therapeutic alternatives
- Claudia E. Guerrero
- Andrea F. Guerrero
- Marcela Paz Sosa
